MedinCell S.A. (FRA:MEB)

Market Cap	843.46M
Revenue (ttm)	32.44M
Net Income (ttm)	-19.95M
Shares Out	n/a
EPS (ttm)	-0.63
PE Ratio	n/a
Forward PE	406.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	20
Open	25.34
Previous Close	25.38
Day's Range	25.04 - 25.34
52-Week Range	12.06 - 37.82
Beta	n/a
RSI	42.05
Earnings Date	Mar 9, 2026

About MedinCell

MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults; and mdc-CWM, a sustained-release formulation of celecoxib in Phase III tria...

• Industry: Pharmaceutical Preparations
• Founded: 2003
• Employees: 131
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: MEB

Financial Performance

In 2024, MedinCell's revenue was 27.73 million, an increase of 132.12% compared to the previous year's 11.95 million. Losses were -18.44 million, -26.36% less than in 2023.